Table 4.

Estimated adjusted HRs (95% CI) for CIN-III and ICC according to baseline categories of serum GGT (VHM&PP, 1985–2003)

	Serum GGT
	Normal low (<17.99 units/L)	Normal high (18.00–35.99 units/L)	Elevated (36.00–71.99 units/L)	Highly elevated (>72.00 units/L)	P for trend across GGT categories*	HR for GGT log unit increase†	P for GGT log unit increase†
CIN-III (n = 702)‡
Events, no. (%)	431/43,588 (1.0)	222/22,230 (1.0)	37/5,375 (0.7)	12/2,161 (0.6)	0.02	1.25 (0.89–1.76)	0.19
HR (95% CI)†	1.00 (Referent)	1.31 (1.11–1.54)	1.20 (0.85–1.69)	1.10 (0.62–1.98)
ICC (n = 117)
Events, no. (%)	35/53,506 (0.1)	54/28,915 (0.2)	18/7,364 (0.2)	10/3,058 (0.3)	<0.0001	3.45 (1.92–6.19)	<0.0001
HR (95% CI)†	1.00 (Referent)	2.31 (1.49–3.59)	2.76 (1.52–5.02)	3.38 (1.63–7.00)

NOTE: Participants with baseline GGT > 600 units/L or with a history of malignancies prior to enrollment were excluded. GGT measurements at first visit were used in the analyses.

^*P values for log linear trend were calculated using baseline GGT categories as an ordinal variable in Cox proportional hazards regression adjusted for age, BMI, occupational status, smoking status, year of entry into the cohort, number of gynecologic examinations, and baseline cytology (within ± 6 mo from baseline GGT measurement).

^†Estimated from Cox proportional hazards regression adjusted for age, BMI, occupational status, smoking status, year of entry into the cohort, number of gynecologic examinations, and baseline cytology (within ± 6 mo from baseline GGT measurement).

^‡Among 73,354 women with one or more gynecologic examinations during follow-up.